Optimizing survival in advanced prostate cancer: CHAARTED: What are the implications for the future?

Bookmark and Share
Sorry, this item is currently unavailable.
Published: 29 Jan 2015
Views: 4038
Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Prof Sweeney discusses the CHAARTED trial (ChemoHormonal Therapy versus Androgen Ablation Randomised Trial for Extensive Disease in Prostate Cancer) and its implications for the treatment of prostate cancer at ESMO 2014.

From the same symposium:

Welcome and introduction

Understanding PC heterogeneity to guide treatment choices

Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to optimise survival

Learnings from real life practice